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Abstract Transmissible spongiform encephalopathy (TSE)
agents or prions induce neurodegenerative fatal diseases in hu-
mans and in some mammalian species. Human TSEs include
Creutzfeldt^Jakob disease (CJD), Gerstmann^Stra«ussler^
Scheinker syndrome, kuru and fatal familial insomnia. In ani-
mals, scrapie in sheep and goats, feline spongiform encephalop-
athy, transmissible mink encephalopathy, chronic wasting dis-
ease in wild ruminants, and bovine spongiform encephalopathy
(BSE), which appeared in the UK in the mid-1980s [Wells,
G.A.H. et al. (1987) Vet. Rec. 121, 419^420], belong to the
TSE group. Prions have biological and physicochemical charac-
teristics that di¡er signi¢cantly from those of other microorgan-
isms; for example, they are resistant to inactivation processes
that are e¡ective against conventional viruses, including those
that alter nucleic acid structure or function. Alternatively, in-
fectivity is highly susceptible to procedures that modify protein
conformation. Today, the exact nature of prions remains un-
known even though it is likely that they consist of protein
only. At the biochemical level, TSEs are characterised by the
accumulation, within the central nervous system of the infected
individual, of an abnormal isoform of a particular protein from
the host, the prion protein [Prusiner, S.B. (1982) Science 216,
136^144]. TSEs are transmissible among their species of origin,
but they can also cross the species barrier and induce chronic
infection and/or disease in other species. Transmissibility has
been proven in natural situations such as the outbreak of CJD
among patients treated with pituitary-derived hormones and the
appearance of BSE that a¡ected UK cattle in the mid-
1980s. @ 2002 Published by Elsevier Science B.V. on behalf
of the Federation of European Biochemical Societies.
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1. Prion: a new form of biological information
The nature of transmissible spongiform encephalopathy
(TSE) agents is still unknown. However, based on animal
model studies in rodents [3], intensive investigation of bio-
chemical and biological properties of prions have been con-
ducted.
The size of TSE agents or prions has been evaluated by
ultra¢ltration to be between 15 and 40 nm [4], although these
agents aggregate easily because of their hydrophobicity; var-
iations in size and density have been reported in the literature.
The inactivation processes that are e¡ective against scrapie
agents are those that denature or hydrolyse protein compo-
nents: treatment with high doses of proteinase K, trypsin [5]
or sodium dodecyl sulphate. Conversely, procedures that in-
teract with nucleic acids do not modify infectivity titres [2].
Moreover, prions are highly resistant to ionising radiations
and their inactivation UV spectrum does not suggest the pres-
ence of a coding nucleic acid [6,7]. Therefore, one may hy-
pothesise that TSE agents are only composed of proteins.
Numerous experimental data indicate the absence of specif-
ic nucleic acids associated with infectivity, although small nu-
cleic acids can be evidenced in both infected and non-infected
control fractions [8]. The theory of a self-propagating proteic
agent, or ‘prion’ (for proteinasceous infectious particle), was
proposed at the end of the 1970s [2] after the puri¢cation of a
27^30 kDa protein speci¢cally associated with infectivity, the
prion protein PrP-sc. This protein is present in infected indi-
viduals in proportion to the level of infection. In fact, PrP-sc
is an abnormal isoform of a normal component of the host,
PrPc [9]. The mechanism by which PrP-sc accumulates is post-
translational and no modulation of PrP gene (Prnp) expres-
sion has ever been reported during natural or experimental
TSEs. PrP-c and PrP-sc do not di¡er in amino acid sequence:
the di¡erences are thought to be at the level of conformation.
PrP-sc is insoluble in detergents, although PrP-c is soluble
[10]. Moreover, PrP-c is totally degraded by proteinase K
concentrations that only partially degrade PrP-sc (Fig. 1).
The amount of PrP-c is 50 times greater in brain than in other
organs; this may be a critical parameter of the pathogenesis of
TSEs [9]. In detergent-treated brain extracts from infected
individuals, ¢brils composed of polymers of PrP-sc, namely
scrapie-associated ¢brils or prion rods, can be evidenced by
electron microscopy [11].
The normal isoform, PrP-c, is anchored at the cell mem-
brane, in rafts, through a glycosyl phosphatidyl inositol
(GPI); its half-life at the cell surface is 5 h, after which the
protein is internalised through a caveolae-dependent mecha-
nism and degraded in the endolysosome compartment [12].
Conversion between PrP-c and PrP-sc occurs likely during
the internalisation process. In humans, PrP is a 253 amino
acid protein, which has a molecular weight of 35^36 kDa. It
has two hexapeptides and repeated octapeptides at the N-ter-
minus, a disulphide bond and is associated at the C-terminus
with a GPI, which enables it to anchor to the external part of
the cell membrane. The fragment of PrP that is resistant to
proteinase K digestion (PrP-res) in infected individuals is be-
tween amino acid residues 90 and 233 (molecular weight 27^
30 kDa). PrP-c has two putative sites of glycosylation; thus,
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three glycoforms of PrP can be described. The relative pro-
portions of these glycoforms and the size of the unglycosy-
lated PrP-res fragment are dependent on the strain of prion
[13]. Infrared spectroscopy and circular dichroism have shown
that the secondary structure of PrP-c is mainly composed of
K-helices, whereas PrP-sc is mainly L-sheets [14] : transconfor-
mation of K-helices into L-sheets has been proposed as the
structural basis by which PrP acquires pathogenicity in
TSEs. The three-dimensional structures of a normal human,
murine, bovine, and hamster PrP have been published [15^
17]: the protein is made of a globular domain (a.a. 121^
231) which includes three K-helices and two small antiparallel
L-sheet structures, and a long £exible tail whose conformation
depends on the biophysical parameters of the environment
Fig. 1. Di¡erential susceptibility of PrP-c and PrP-sc to proteinase K digestion.
Fig. 2. Three-dimensional structure of the cellular PrP.
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(Fig. 2). Crystals of the globular domain of PrP have recently
been obtained; their analysis suggests a possible dimerisation
of the protein through the three-dimensional swapping of the
C-terminal helix 3 and rearrangement of the disulphide bond
[18]. In vitro conversion of PrP-c into a protease-resistant
isoform is possible in an acellular experimental system [19].
Several hypotheses have been proposed to explain the na-
ture of the TSE agents and the pathogenesis of TSE:
b The virino hypothesis [20], which suggests that the agent
consists of a nucleic acid, which codes only for its own
replication surrounded by host-encoded PrP (thus account-
ing for the lack of an immune response);
b The unknown conventional virus hypothesis; current con-
cepts of microbiology indicate that this is most unlikely;
and
b The protein-only hypotheses that include the seeding mod-
el, the chaperone-disease model and the prion theory.
The protein-only hypotheses are supported by the most
recent results from transgenic experiments and molecular bi-
ology. In these theories, PrP-sc is the agent, or a major com-
ponent of infectivity [2]. The prion theory postulates that
pathogenicity is enciphered into the tertiary structure of
PrP-sc. Propagation of the abnormal conformation results
from the ability of PrP-sc to form dimers with PrP-c; this
heterodimerisation induces a transconformation of PrP-c
into PrP-sc, and, therefore, the propagation of this abnormal
isoform of PrP (i.e. PrP-sc). Recently, it has been suggested
that PrP-c transconformation into PrP-sc requires a host-en-
coded cellular factor, factor X [21], which is thought to be a
chaperone (Fig. 3).
Other theories involving chaperoning molecules [22] or nu-
cleation have also been proposed [23] ; in this last hypothesis,
the transformation of PrP-c into PrP-sc is reversible, PrP-sc
being stable only when aggregated. Then, binding of PrP-c to
PrP-sc aggregates results in PrP-c transconformation. The size
of the aggregate then increases until the limit of cohesion of
the aggregate, above which a dissociation occurs, giving birth
to small seeds e⁄cient for PrP-c transconformation.
Wu«thrich et al. have proposed that the excess of L-sheet
measured in PrP-sc could be the consequence of aggregation
through the globular domains which could trap a part of the
£exible tail inside the aggregate and therefore induce a L-sheet
conformation of a part of the molecule that was not struc-
tured before; if demonstrated, this mechanism would not re-
quire any transconformation process of PrP.
2. The role of the prion protein
The precise function of the normal PrP isoform in healthy
individuals remains unknown. Several results, mainly ob-
tained in transgenic animals, indicate that PrP-c might play
a role in long-term potentiation, in sleep physiology, in oxi-
dative burst compensation (PrP can ¢x four Cu2þ through its
octarepeat domain) [24], in interactions with the extracellular
matrix (PrP-c can bind to the precursor of the laminin recep-
tor, LRP) [25], in apoptosis and in signal transduction (co-
stimulation of PrP-c induces a modulation of Fyn kinase
phosphorylation) [26]. Recently, interactions between PrP
and retroviral nucleic acids have been reported [27,28].
In TSE-a¡ected individuals, PrP has a determinant role in
the incubation time and in the species barrier [29] and its role
in pathogenesis is now established. Transgenic mice lacking
Prnp expression (i.e. knockout mice that do not express any
PrP) are not susceptible to TSE agent or prion infection,
demonstrating the key role of PrP in TSEs [29]. Susceptibility
to prions thus depends upon the presence of PrP-c on the cell
membrane of the host; prions do not propagate in brains that
lack PrP-c [30]. Moreover, in transgenic animals that express
large numbers of PrP gene (Prnp) copies, incubation time is
inversely correlated with PrP-c expression; that is, susceptibil-
ity to infection and prion propagation depend on the amount
of PrP-c available in the host. Finally, transgenic animals with
Fig. 3. The prion hypothesis.
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a PrP gene mutation equivalent to one described in human
familial disease spontaneously exhibit a spongiform encepha-
lopathy that is transmissible under certain conditions [31].
3. Prion disease pathogenesis
Natural and experimental TSEs are characterised by a long
incubation phase without clinical symptoms: this silent phase
may last as long as 40 years in humans with kuru or infected
through extracted growth hormone treatment. Once started,
the clinical course of the disease evolves slowly without remis-
sion. No in£ammatory process is identi¢able in blood or
CSF; none of the usual immunological stigma or speci¢c signs
of chronic viral infections are observed in infected individuals.
No virus-like or micro-organism-like structure is identi¢able
in the brains of infected patients, regardless of which micro-
scopic technique is used.
The intracerebral route is the most e¡ective for prion con-
tamination and the oral route is the least e¡ective (1 intra-
cerebral route infectious unit = 125 000 oral route infectious
units) [32] ; this has been demonstrated in experimental mod-
els, but natural disease-associated agents, especially the bovine
spongiform encephalopathy (BSE) agent [1], may behave dif-
ferently and be more infectious by a peripheral route (includ-
ing oral exposure). In vivo, there are no alterations of the B,
T, and non-T-non-B cells (quantitative or functional) and no
antibody against PrP has been detected in natural or exper-
imental diseases; therefore, there is no test available for
screening asymptomatic infected individuals.
Transmissibility is easy inside the same species, but is also
possible between di¡erent species. The strength of the species
barrier is variable; for example, BSE is not transmissible to
hamsters although it can be easily transmitted to mice. The
major molecular determinant of the species barrier is the ho-
mology between the PrP gene of the donor and the PrP gene
of the recipient; other genes play minor roles in TSE agent or
prion susceptibility, for example major histocompatibility
genes. In humans, the PrP gene exhibits a polymorphism at
codon 129; either valine or methionine can be encoded, 50%
of the general population being homozygous. Homozygosity
at codon 129 has been associated with susceptibility to spo-
radic iatrogenic and variant Creutzfeldt^Jakob disease (CJD)
[33].
The kinetics of PrP-res accumulation has been studied in a
number of experimental animal models. Results have con-
¢rmed that accumulation follows the increase in infection.
Infectivity distribution depends upon the route of inoculation,
the strain of prion, the dose of inoculum and the genetic
background of the host. For example, after peripheral expo-
sure, the TSE agent is detectable in the lymphoid system of
infected animals soon after inoculation; it then appears in the
central nervous system during the second half of the total
duration of the experimental disease.
These facts illustrate two main characteristics of the trans-
missible spongiform encephalopathies:
b Certain organs of the infected individual, particularly the
brain, spinal cord and retina, are heavily infected before
clinical signs appear [34], and
b These diseases develop without interruption, that is, with-
out any latency of the infectious agent during the asympto-
matic phase.
The immune system plays a role during the pathogenesis of
peripheral infection with TSE agents. Immune cells (most
probably dendritic cells and macrophages [35,36]) can be the
¢rst site of replication of these agents. In secondary lymphoid
structures, infectivity is associated with follicular dendritic
cells (FDCs); FDCs are critical in the neuroinvasion processes
[37]. Neuroinvasion then occurs through the nerve endings
that are present in lymphoid organs. It is not known if PrP-
sc propagates in the peripheral nervous system (PNS) via a
retroaxonal transport or through a propagation of abnormal
conformation following a ‘domino model’ at the surface of the
axon or of the Schwann cells [38] ; the presence of PrP-c is
required for agent propagation in the PNS [39].
Neuropathology of TSEs consists of neuronal death, spon-
giosis and gliosis with hyperastrocytosis. The precise mecha-
nisms that lead to brain cell damage are not known. Never-
theless, several experimental results indicate that neuronal
death can occur in two ways: by accumulation of PrP-sc in
the cytoplasm through a toxic mechanism; and by apoptosis
of non-infected neurones induced by PrP. Indeed, exposure of
primary neuronal cell cultures to peptides derived from the
106^126 domain of the PrP molecule induces apoptosis [40].
This apoptosis requires the presence of microglial cells and the
presence of PrP-c at the cell surface; the apoptotic pathway
requires N-methyl-D-aspartate receptor activation. Microglial
cells exposed to PrP 106^126 or to PrP-sc secrete IL-1 L, IL-6
and other neurotoxic mediators that could participate in neu-
ronal death observed during TSEs. On the other hand, expo-
sure of primary astrocyte cell culture to PrP-sc in liposomes
induces astrocyte activation and hyperexpression of the glial
¢brillary acidic protein gene, which is a biochemical hallmark
of natural and experimental TSE (unpublished data).
4. Conclusion
Human TSEs are rare diseases, CJD being the most com-
mon. CJD incidence does not di¡er signi¢cantly among coun-
tries [41] ; incidence ranges between 1 and 1.7 per million in-
habitants per year. To date, no link has been described with
animal TSE except for the new variant of CJD (vCJD) [42],
which occurred mainly in the UK and is thought to be caused
by the BSE agent [43^45]. Several clusters of CJD have been
described in the past, especially in Slovakia and Israel. Prog-
ress in molecular genetics has demonstrated that these clusters
were in fact inherited forms of CJD; it should be noted that
all forms of human TSEs are transmissible, including the ge-
netic diseases. Several iatrogenic accidents have been reported
in the literature [46], underlying the absolute need of preven-
tion in daily medical and surgical practice; one has to keep in
mind that no treatment exists today for TSEs, although a few
drugs have proved relatively e¡ective when administered at
the time of the experimental infection (Congo red, dextran
sulphate, tungstoantimoniate, amphothericin B and its deriv-
atives). [47,48]
Since 1996, 125 cases of a new variant of CJD have been
reported in young individuals in the UK [42]. In this disease,
PrP-sc and infectivity can be detected in lymphoid organs of
the a¡ected patients (tonsils, lymph nodes, appendix) [49,50] ;
this demonstrates the role of the lymphoid system in periph-
eral oral infection in humans exposed to the BSE agent and
this distribution of infectivity in periphery has numerous pub-
lic health consequences, the size of which will depend on the
number of future cases of vCJD.
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